Table 3. Open in new tab Subgroup...

Factor

Arm

Events/No.

2-y OS (95% CI)

HR (95% CI)

Age, y

≤60

7/25

88.0 (67.3–96.0)

8/25

76.0 (54.2–88.4)

1.315 (0.476–3.632)

≥61

16/37

85.8 (69.2–93.8)

14/35

76.4 (58.3–87.5)

1.010 (0.492–2.074)

PS at second registration

0–1

15/44

88.1 (73.7–94.9)

13/44

81.8 (66.8–90.4)

0.901 (0.429–1.896)

2–3

8/18

83.3 (56.8–94.3)

9/16

59.6 (30.8–79.6)

1.838 (0.701–4.817)

Sex

Male

13/40

92.1 (77.5–97.4)

14/35

76.4 (58.3–87.5)

1.393 (0.653–2.970)

Female

10/22

77.3 (53.7–89.8)

8/25

75.8 (53.8–88.3)

0.750 (0.295–1.908)

Ocular disease

–

22/55

86.9 (74.4–93.5)

20/53

72.9 (58.6–83.0)

1.075 (0.586–1.972)

1/7

85.7 (33.4–97.9)

2/7

100.0 (100.0–100.0)

1.901 (0.172–20.996)

Lesion at the first registration

Single

11/27

88.5 (68.4–96.1)

10/30

76.5 (57.0–88.1)

0.941 (0.398–2.223)

Multiple

12/35

85.3 (68.2–93.6)

12/30

76.2 (56.5–87.9)

1.334 (0.598–2.976)

RPA subgroup

3/8

75.0 (31.5–93.1)

1/5

80.0 (20.4–96.9)

0.518 (0.054–4.989)

13/38

91.7 (76.3–97.2)

10/33

78.2 (59.7–89.0)

0.927 (0.406–2.117)

7/16

81.3 (52.5–93.5)

11/22

72.2 (48.2–86.5)

1.490 (0.574–3.869)

Response to HD-MTX
by central review

PR, SD, PD

15/38

89.3 (73.8–95.8)

15/40

74.3 (57.5–85.3)

1.164 (0.568–2.384)

CR/CRu

4/14

76.9 (44.2–91.9)

2/9

77.8 (36.5–93.9)

0.798 (0.146–4.360)

MGMT

Hypomethylated

14/31

83.3 (64.5–92.7)

9/26

72.2 (50.4–85.7)

0.888 (0.384–2.053)

Hypermethylated

9/29

89.7 (71.3–96.5)

12/29

78.9 (58.8–89.9)

1.432 (0.601–3.409)

Table 3.

Open in new tab

Subgroup Analyses of OS

Factor		Arm	Events/No.	2-y OS (95% CI)	HR (95% CI)
Age, y	≤60	A	7/25	88.0 (67.3–96.0)	1
		B	8/25	76.0 (54.2–88.4)	1.315 (0.476–3.632)
	≥61	A	16/37	85.8 (69.2–93.8)	1
		B	14/35	76.4 (58.3–87.5)	1.010 (0.492–2.074)
PS at second registration	0–1	A	15/44	88.1 (73.7–94.9)	1
		B	13/44	81.8 (66.8–90.4)	0.901 (0.429–1.896)
	2–3	A	8/18	83.3 (56.8–94.3)	1
		B	9/16	59.6 (30.8–79.6)	1.838 (0.701–4.817)
Sex	Male	A	13/40	92.1 (77.5–97.4)	1
		B	14/35	76.4 (58.3–87.5)	1.393 (0.653–2.970)
	Female	A	10/22	77.3 (53.7–89.8)	1
		B	8/25	75.8 (53.8–88.3)	0.750 (0.295–1.908)
Ocular disease	–	A	22/55	86.9 (74.4–93.5)	1
		B	20/53	72.9 (58.6–83.0)	1.075 (0.586–1.972)
	+	A	1/7	85.7 (33.4–97.9)	1
		B	2/7	100.0 (100.0–100.0)	1.901 (0.172–20.996)
Lesion at the first registration	Single	A	11/27	88.5 (68.4–96.1)	1
		B	10/30	76.5 (57.0–88.1)	0.941 (0.398–2.223)
	Multiple	A	12/35	85.3 (68.2–93.6)	1
		B	12/30	76.2 (56.5–87.9)	1.334 (0.598–2.976)
RPA subgroup	1	A	3/8	75.0 (31.5–93.1)	1
		B	1/5	80.0 (20.4–96.9)	0.518 (0.054–4.989)
	2	A	13/38	91.7 (76.3–97.2)	1
		B	10/33	78.2 (59.7–89.0)	0.927 (0.406–2.117)
	3	A	7/16	81.3 (52.5–93.5)	1
		B	11/22	72.2 (48.2–86.5)	1.490 (0.574–3.869)
Response to HD-MTX by central review	PR, SD, PD	A	15/38	89.3 (73.8–95.8)	1
		B	15/40	74.3 (57.5–85.3)	1.164 (0.568–2.384)
	CR/CRu	A	4/14	76.9 (44.2–91.9)	1
		B	2/9	77.8 (36.5–93.9)	0.798 (0.146–4.360)
MGMT	Hypomethylated	A	14/31	83.3 (64.5–92.7)	1
		B	9/26	72.2 (50.4–85.7)	0.888 (0.384–2.053)
	Hypermethylated	A	9/29	89.7 (71.3–96.5)	1
		B	12/29	78.9 (58.8–89.9)	1.432 (0.601–3.409)

Factor		Arm	Events/No.	2-y OS (95% CI)	HR (95% CI)
Age, y	≤60	A	7/25	88.0 (67.3–96.0)	1
		B	8/25	76.0 (54.2–88.4)	1.315 (0.476–3.632)
	≥61	A	16/37	85.8 (69.2–93.8)	1
		B	14/35	76.4 (58.3–87.5)	1.010 (0.492–2.074)
PS at second registration	0–1	A	15/44	88.1 (73.7–94.9)	1
		B	13/44	81.8 (66.8–90.4)	0.901 (0.429–1.896)
	2–3	A	8/18	83.3 (56.8–94.3)	1
		B	9/16	59.6 (30.8–79.6)	1.838 (0.701–4.817)
Sex	Male	A	13/40	92.1 (77.5–97.4)	1
		B	14/35	76.4 (58.3–87.5)	1.393 (0.653–2.970)
	Female	A	10/22	77.3 (53.7–89.8)	1
		B	8/25	75.8 (53.8–88.3)	0.750 (0.295–1.908)
Ocular disease	–	A	22/55	86.9 (74.4–93.5)	1
		B	20/53	72.9 (58.6–83.0)	1.075 (0.586–1.972)
	+	A	1/7	85.7 (33.4–97.9)	1
		B	2/7	100.0 (100.0–100.0)	1.901 (0.172–20.996)
Lesion at the first registration	Single	A	11/27	88.5 (68.4–96.1)	1
		B	10/30	76.5 (57.0–88.1)	0.941 (0.398–2.223)
	Multiple	A	12/35	85.3 (68.2–93.6)	1
		B	12/30	76.2 (56.5–87.9)	1.334 (0.598–2.976)
RPA subgroup	1	A	3/8	75.0 (31.5–93.1)	1
		B	1/5	80.0 (20.4–96.9)	0.518 (0.054–4.989)
	2	A	13/38	91.7 (76.3–97.2)	1
		B	10/33	78.2 (59.7–89.0)	0.927 (0.406–2.117)
	3	A	7/16	81.3 (52.5–93.5)	1
		B	11/22	72.2 (48.2–86.5)	1.490 (0.574–3.869)
Response to HD-MTX by central review	PR, SD, PD	A	15/38	89.3 (73.8–95.8)	1
		B	15/40	74.3 (57.5–85.3)	1.164 (0.568–2.384)
	CR/CRu	A	4/14	76.9 (44.2–91.9)	1
		B	2/9	77.8 (36.5–93.9)	0.798 (0.146–4.360)
MGMT	Hypomethylated	A	14/31	83.3 (64.5–92.7)	1
		B	9/26	72.2 (50.4–85.7)	0.888 (0.384–2.053)
	Hypermethylated	A	9/29	89.7 (71.3–96.5)	1
		B	12/29	78.9 (58.8–89.9)	1.432 (0.601–3.409)

CI, confidence interval; CR, complete response; CRu, complete response unconfirmed; HD-MTX, high-dose methotrexate; HR, hazard ratio; MGMT, O⁶-methylguanine-DNA methyltransferase; OS, overall survival; PD, progressive disease; PR, partial response; PS, performance status; RPA, recursive partitioning analysis; SD, stable disease

This Feature Is Available To Subscribers Only